Essential oil of Melaleuca alternifolia for the treatment of oral candidiasis induced in an immunosuppressed mouse model

被引：22

作者：

de Campos Rasteiro V.M. ^{[1
]}

da Costa A.C.B.P. ^{[1
]}

Araújo C.F. ^{[1
]}

de Barros P.P. ^{[1
]}

Rossoni R.D. ^{[1
]}

Anbinder A.L. ^{[1
]}

Jorge A.O.C. ^{[1
]}

Junqueira J.C. ^{[1
]}

机构：

[1] Department of Biosciences and Oral Diagnosis, Institute of Science and Technology, UNESP - Univ Estadual Paulista, Francisco Jose Longo 777, Sao Dimas, Sao Jose dos Campos, Kragujevac, SP

来源：

BMC Complementary and Alternative Medicine | / 14卷 / 1期

基金：

巴西圣保罗研究基金会;

关键词：

Candida albicans; Melaleuca alternifolia; Murine model; Oral candidiasis;

D O I：

10.1186/1472-6882-14-489

中图分类号：

学科分类号：

摘要：

Background: The search for alternative therapies for oral candidiasis is a necessity and the use of medicinal plants seems to be one of the promising solutions. The objective of this study was to evaluate the in vitro and in vivo effects of the essential oil of Melaleuca alternifolia on Candida albicans. Methods: The minimum inhibitory concentration (MIC) and minimum biofilm eradication concentration (MBEC) of M. alternifolia were determined by the broth microdilution assay. For the in vivo study, twelve immunosuppressed mice with buccal candidiasis received topical applications of M. alternifolia with MBEC. After treatment, yeasts were recovered from the mice and quantified (CFU/mL). Mice were killed for morphologic analysis of the tongue dorsum by optical and scanning electron microscopy. Data were analyzed using Student's t test or Mann-Whitney test. Results: The MIC of M. alternifolia was 0.195% and the MBEC was 12.5%. Treatment with M. alternifolia achieved a 5.33 log reduction in C. albicans and reduced the microscopic lesions of candidiasis. Conclusions: M. alternifolia oil at a 12.5% was effective to eradicate a C. albicans biofilm formed in vitro and to reduce yeasts of C. albicans in an immunosuppressed mouse model. © 2014 de Campos Rasteiro et al.

引用

共 39 条

[31]

Greay S.J., Ireland D.J., Kissick H.T., Inhibition of established subcutaneous murine tumour growth with topical Melaleuca alternifolia (tea tree) oil, Cancer Chemother Pharmacol, 66, pp. 1095-1102, (2010)

[32]

Veien N.K., Rosner K., Skovgaard G.L., Is tea tree oil an important contact allergen?, Contact Dermatitis, 50, pp. 378-379, (2004)

[33]

Catalan A., Pacheco J.G., Martinez A., Mondaca M.A., In vitro and in vivo activity of Melaleuca alternifolia mixed with tissue conditioner on Candida albicans, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 105, pp. 327-332, (2008)

[34]

Morris M.C., Donoghue A., Markowitz J., Osterhoudt K.C., Ingestion of tea tree oil (Melaleuca oil) by a 4-year-old boy, Pediatr Emerg Care, 19, pp. 169-171, (2003)

[35]

Moss A., Tea tree oil poisoning, Med J Aust, 160, (1994)

[36]

Ninomiya K., Hayama K., Ishijima A.S., Maruyama N., Irie H., Kurihara J., Abe S., Suppression of inflammatory reactions by Terpinen-4-ol, a main constituent of Tea Tree Oil, in a murine model of oral candidiasis and its suppressive activity to cytokine production of macrophages in vitro, Biol Pharm Bull, 36, pp. 838-844, (2013)

[37]

Arechabala B., Coiffard C., Rivalland P., Coiffard L.J., de Roeck-Holtzhauer Y., Comparison of cytotoxicity of various surfactants tested on normal human fibroblast cultures using the neutral red test, MTT assay and LDH release, J Appl Toxicol, 19, pp. 163-165, (1999)

[38]

Bulcao R.P., de Freitas F.A., Dallegrave E., Venturini C.G., Baierle M., Durgante J., Sauer E., Cassini C., Cerski C.T., Zielinsky P., Salvador M., Pohlmann A.R., Guterres S.S., Garcia S.C., In vivo toxicological evaluation of polymeric nanocapsules after intradermal administration, Eur J Pharm Biopharm, 86, pp. 167-177, (2014)

[39]

Hisajima T., Ishibashi H., Yamada T., Nishiyama Y., Yamaguchi H., Funakoshi K., Abe S., Invasion process of Candida albicans to tongue surface in early stages of experimental murine oral candidiasis, Med Mycol, 46, pp. 697-704, (2008)

← 1 2 3 4 →